Eris Lifesciences Limited ERIS NIFTY_SMALLNSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India

https://www.eris.co.in

Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as antidiabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women's health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram measurement, continuous glucose monitoring system, sleep study, and anti-natal care solutions. It offers its products through wholesale drug distributors, stockists, retail and e-commerce pharmacies. Eris Lifesciences Limited was incorporated in 2007 and is headquartered in Ahmedabad, India.

Market & Price

Market Cap

₹19,385.56 Cr

Current Price

₹1,399.00

High / Low (52W)

₹1,847.70 / ₹1,271.00

Beta

-0.12

Valuation

Stock P/E

30.86

Industry PE

37.60

Forward P/E

22.43

PEG Ratio

Book Value

₹226.84

Price to Book

6.17

P/S

6.22

EV/EBITDA

19.11

Dividend Yield

1.03%

Profitability & Returns

ROCE

15.72%

ROE

18.07%

ROA

7.30%

Profit Margin

19.89%

Op Margin

27.12%

EPS (Latest Qtr)

₹20.57

EPS (TTM)

₹45.33

Balance Sheet & Liquidity

Debt/Equity

0.61

Quick Ratio

0.36

Current Ratio

0.74

Debt

₹2,358.62 Cr

Total Assets

₹7,365.51 Cr

Current Assets

₹1,539.85 Cr

Working Capital

₹-537.25 Cr

Ownership

Promoter Holding

69.70%

Chg in Prom Hold

1.66%

FII / Inst Holding

22.71%

Chg in FII Hold

0.61%

Financial Snapshot

Enterprise Value

₹21,409.18 Cr

Total Revenue (TTM)

₹3,114.89 Cr

EBITDA

₹1,120.11 Cr

Free Cash Flow

₹-30.12 Cr

Operating Cash Flow

₹537.99 Cr

Shares Outstanding

₹13.86 Cr

Gross Margin

74.46%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

23.30%

Profit 5Y

17.47%

Revenue (YoY)

7.10%

Earnings (YoY)

200.00%

PROS

Compounding revenue at 23.3% over 5 years.
Profit CAGR of 17.5% over 5 years.

CONS

In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	ERIS Eris Lifesciences Limited NIFTY_SMALLNSEPHARMA	1,399.00	30.86	₹19,385.56 Cr	1.03%	15.72%	18.07%	23.30%	17.47%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,799.20	37.59	₹4.32 L Cr	0.92%	17.94%	14.72%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	6,667.00	68.97	₹1.77 L Cr	0.45%	18.96%	16.19%	11.27%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,410.80	68.96	₹1.49 L Cr	0.86%	9.06%	16.98%	13.27%	20.21%
5	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,401.00	29.16	₹1.13 L Cr	0.93%	14.88%	11.74%	7.23%	11.45%
6	DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA	1,303.50	25.90	₹1.09 L Cr	0.61%	14.00%	11.83%	10.96%	-2.35%
7	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,077.70	21.51	₹1.08 L Cr	0.09%	19.24%	18.32%	16.55%	36.99%
8	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,267.70	19.49	₹1.04 L Cr	0.53%	28.42%	26.91%	19.10%	131.46%
9	MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA	2,375.60	51.29	₹98,090.71 Cr	0.08%	13.78%	12.45%	17.73%	14.28%

Quarterly Results

Figures in INR.

Metric	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	702.60 Cr	771.56 Cr	790.15 Cr	800.89 Cr	752.29 Cr
Cost of Revenue	-	170.25 Cr	184.64 Cr	202.41 Cr	223.30 Cr	185.25 Cr
Gross Profit	-	532.35 Cr	586.92 Cr	587.74 Cr	577.59 Cr	567.04 Cr
Operating Expenses	-	357.16 Cr	380.72 Cr	368.61 Cr	366.32 Cr	362.95 Cr
Operating Income	-	175.19 Cr	206.20 Cr	219.13 Cr	211.27 Cr	204.09 Cr
EBITDA	-	260.35 Cr	280.29 Cr	291.30 Cr	264.51 Cr	274.60 Cr
Interest Expense	-	54.28 Cr	48.68 Cr	49.55 Cr	48.82 Cr	45.62 Cr
Pretax Income	-	128.87 Cr	161.10 Cr	172.67 Cr	145.35 Cr	159.41 Cr
Tax Provision	-	26.52 Cr	36.00 Cr	38.20 Cr	36.52 Cr	-119.69 Cr
Net Income	-	93.84 Cr	117.99 Cr	120.19 Cr	99.72 Cr	281.61 Cr
Diluted EPS	-	6.89	8.64	8.81	7.32	20.57

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue	-	1,661.82 Cr	1,991.30 Cr	2,879.26 Cr	3,114.89 Cr
Cost of Revenue	-	357.08 Cr	387.64 Cr	713.99 Cr	795.60 Cr
Gross Profit	-	1,304.74 Cr	1,603.66 Cr	2,165.27 Cr	2,319.29 Cr
Operating Expenses	-	882.55 Cr	1,108.25 Cr	1,463.53 Cr	1,478.71 Cr
Operating Income	-	422.19 Cr	495.41 Cr	701.74 Cr	840.58 Cr
EBITDA	-	547.90 Cr	698.65 Cr	1,035.62 Cr	1,110.71 Cr
Interest Expense	-	26.17 Cr	84.80 Cr	231.29 Cr	192.67 Cr
Pretax Income	-	404.64 Cr	431.34 Cr	488.87 Cr	638.54 Cr
Tax Provision	-	30.48 Cr	34.22 Cr	114.20 Cr	-8.97 Cr
Net Income	-	382.16 Cr	392.05 Cr	351.84 Cr	619.50 Cr
Diluted EPS	-	28.07	28.79	25.81	45.26

Compounded Sales Growth

5 Years:	23.30%
1 Year:	7.10%

Compounded Profit Growth

5 Years:	17.47%
1 Year:	200.00%

Stock Price Performance

1 Year:	-13.41%
6 Months:	-16.21%
3 Months:	+4.22%
1 Month:	+5.38%

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Assets	-	3,667.33 Cr	7,040.46 Cr	7,033.17 Cr	7,365.51 Cr
Current Assets	-	764.72 Cr	2,302.04 Cr	1,222.99 Cr	1,539.85 Cr
Cash & Equivalents	-	55.95 Cr	94.14 Cr	199.64 Cr	54.74 Cr
Inventory	-	131.44 Cr	189.03 Cr	334.83 Cr	436.82 Cr
Receivables	-	292.71 Cr	422.03 Cr	458.64 Cr	680.34 Cr
Total Liabilities	-	1,446.65 Cr	3,818.37 Cr	3,761.41 Cr	3,469.85 Cr
Current Liabilities	-	443.23 Cr	2,532.07 Cr	1,381.39 Cr	2,077.10 Cr
Long Term Debt	-	644.45 Cr	654.51 Cr	1,737.51 Cr	955.83 Cr
Total Debt	-	876.71 Cr	2,781.28 Cr	2,477.92 Cr	2,358.62 Cr
Total Equity	-	2,195.99 Cr	2,586.18 Cr	2,854.36 Cr	3,902.67 Cr
Shares Outstanding	-	13.60 Cr	13.60 Cr	13.62 Cr	13.85 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow	-	291.74 Cr	486.01 Cr	1,065.01 Cr	537.99 Cr
Investing Cash Flow	-	-982.10 Cr	-1,854.52 Cr	-79.97 Cr	-369.46 Cr
Financing Cash Flow	-	688.02 Cr	1,379.78 Cr	-881.32 Cr	-313.53 Cr
Capital Expenditure	-	-841.42 Cr	-129.16 Cr	-155.00 Cr	-296.86 Cr
Free Cash Flow	-	-549.68 Cr	356.85 Cr	910.01 Cr	241.13 Cr
Net Change in Cash	-	-2.34 Cr	11.27 Cr	103.72 Cr	-145.00 Cr

Ratios (Annual)

Figures in %.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Gross Margin %	-	78.5%	80.5%	75.2%	74.5%
Operating Margin %	-	25.4%	24.9%	24.4%	27.0%
Net Margin %	-	23.0%	19.7%	12.2%	19.9%
ROE %	-	17.4%	15.2%	12.3%	15.9%
ROCE %	-	13.1%	11.0%	12.4%	15.9%

Shareholding Pattern

Insiders

69.70%

Institutions

22.71%

Public Float

74.93%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ERIS

No recent headlines available.

ERIS · Healthcare